mTOR抑制剂依维莫司联合内分泌治疗在老年乳腺癌中的研究进展
摘要
<正>乳腺癌是女性最常见的恶性肿瘤,也是癌症死亡的主要原因,据估计2018年女性乳腺癌新诊断病例约为210万例[1]。年龄是乳腺癌的独立危险因素,乳腺癌发病率和死亡率随着年龄的增长而增加[2]。与年轻病人相比,老年人乳腺癌的预后较差,生存率较低[3]。除了年龄因素,经济发展、社会环境、生活习惯等的改变也造成我国老年乳腺癌发病率逐年上升[4],因此积极治疗老年乳腺癌并提高其生活质量迫在眉睫。多数老年乳腺癌病人因激素受体(HR)阳性及人表皮生长因子受体-2(HER2)阴性[5]而选择内分泌治
引文
[1]Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2]Gosain R, Pollock Y, Jain D. Age-related disparity:breast cancer in the elderly[J]. Curr Oncol Rep, 2016, 18(11):69.
[3]Tesarova P. Breast cancer in the elderly-Should it be treated differently?[J]. Rep Pract Oncol Radiother, 2012, 18(1):26-33.
[4]李贺,郑荣寿,张思维,等. 2014年中国女性乳腺癌发病与死亡分析[J].中华肿瘤杂志, 2018, 40(3):166-171.
[5]Pierga JY, Girre V, Laurence V, et al. Characteristics and outcome of 1755 operable breast cancers in women over 70years of age[J]. Breast, 2004, 13(5):369-375.
[6]隋佳琪,谢鲲鹏,谢明杰.乳腺癌相关的细胞内信号通路[J].中国生物化学与分子生物学学报, 2015, 31(1):20-27.
[7]刘程,刘伟光,张磊,等.乳腺癌内分泌治疗耐药相关信号通路的研究进展[J].现代肿瘤医学, 2017, 25(9):1480-1485.
[8]Ghayad SE, Cohen PA. Inhibitors of the PI3K/AKT/mTOR pathway:new hope for breast cancer patients[J]. Recent Pat Anticancer Drug Discov, 2010,5(1):29-57.
[9]LoRusso PM. Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment[J]. Oncology,2013, 84(1):43-56.
[10]冯萍,陈斌,王亚兵. mTOR信号通路途径与乳腺癌[J].黑龙江医药, 2012, 25(6):842-844.
[11] Gombos A, Barthlmy P, Awada A. Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer[J]. Expert Opin Drug Metab Toxicol, 2015,11(5):823-834.
[12]汤琦,陈德滇,蔡尚立,等.乳腺癌内分泌治疗耐药分子机制的研究进展[J].中华乳腺病杂志:电子版, 2018, 12(5):306-311.
[13] Farzaneh S, Zarghi A. Estrogen receptor ligands:a review(2013-2015)[J].Sci Pharm, 2016, 84(3):409-427.
[14] Pejerrey SM, Dustin D, Kim JA, et al. The impact of ESR1mutations on the treatment of metastatic breast cancer[J].Horm Cancer, 2018, 9(4):215-228.
[15] Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer[J]. Nat Genetm,2013, 45(12):1439-1445.
[16]邓颖斐,薛聪,安欣,等.依维莫司和氟维司群在内分泌耐药晚期乳腺癌中的疗效对比[J].实用医学杂志,2018, 34(10):1581-1584.
[17] Yamnik RL, Holz MK. mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation[J]. Febs Letters, 2010, 584(1):124-128.
[18] Bostner J, Karlsson E, Pandiyan MJ, et al. Activation of Akt,mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit[J]. Breast Cancer Res Treat, 2013, 137(2):397-406.
[19] Simoncini T, Hafezi-Moghadam A, Brazil DP, et al.Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase[J]. Nature, 2000, 407(6803):538-541.
[20] Santen RJ, Fan P, Zhang Z, et al. Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and-resistant breast cancer cells[J].Steroids, 2009, 74(7):586-594.
[21] Yamnik RL, Digilova A, Davis DC, et al. S6 kinase 1 regulates estrogen receptorαin control of breast cancer cell proliferation[J]. J Biol Chem, 2009, 284(10):6361-6369.
[22]李惠平.依维莫司在激素受体阳性晚期乳腺癌治疗中的应用[J].中国新药杂志, 2013, 22(17):2043-2045, 2052.
[23] Zhao M, Ramaswamy B. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer[J]. World J Clin Oncol, 2014, 5(3):248-262.
[24] Hortobagyi GN. Everolimus plus exemestane for the treatment of advanced breast cancer:a review of subanalyses from BOLERO-2[J]. Neoplasia, 2015, 17(3):279-288.
[25] Pritchard KI, Burris HA,Ito Y, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2[J]. Clin Breast Cancer, 2013,13(6):421-432.
[26] Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+)breast cancer:BOLERO-2 final progressionfree survival analysis[J]. Adv Ther, 2013, 30(10):870-884.
[27] Porta C, Osanto S, Ravaud A, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma[J]. Eur J Cancer, 2011, 47(9):1287-1298.
[28] Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma:review of adverse event management strategies[J]. J Natl Cancer Inst, 2012, 104(2):93-113.
[29] Jerusalem G, Mariani G, Ciruelos EM, et al. Safety of everolimus plus exemestane in patients with hormonereceptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors:primary results of a phaseⅢb, openlabel, single-arm, expanded-access multicenter trial(BALLET)[J]. Ann Oncol, 2016, 27(9):1719-1725.
[30] Bachelot T, Bourgier C, Cropet C, et al. Randomized phaseⅡtrial of everolimus in combination with tamoxifen in patients with hormone receptorpositive, human epidermal growth factor receptor 2-negativemetastatic breastcancer with prior exposure to aromatase inhibitors:a GINECO study[J].J Clin Oncol, 2012, 30(22):2718-2724.
[31] Royce M, Bachelot T, Villanueva C, et al. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer:A clinical trial[J]. JAMA Oncol, 2018, 4(7):977-984.
[2]Gosain R, Pollock Y, Jain D. Age-related disparity:breast cancer in the elderly[J]. Curr Oncol Rep, 2016, 18(11):69.
[3]Tesarova P. Breast cancer in the elderly-Should it be treated differently?[J]. Rep Pract Oncol Radiother, 2012, 18(1):26-33.
[4]李贺,郑荣寿,张思维,等. 2014年中国女性乳腺癌发病与死亡分析[J].中华肿瘤杂志, 2018, 40(3):166-171.
[5]Pierga JY, Girre V, Laurence V, et al. Characteristics and outcome of 1755 operable breast cancers in women over 70years of age[J]. Breast, 2004, 13(5):369-375.
[6]隋佳琪,谢鲲鹏,谢明杰.乳腺癌相关的细胞内信号通路[J].中国生物化学与分子生物学学报, 2015, 31(1):20-27.
[7]刘程,刘伟光,张磊,等.乳腺癌内分泌治疗耐药相关信号通路的研究进展[J].现代肿瘤医学, 2017, 25(9):1480-1485.
[8]Ghayad SE, Cohen PA. Inhibitors of the PI3K/AKT/mTOR pathway:new hope for breast cancer patients[J]. Recent Pat Anticancer Drug Discov, 2010,5(1):29-57.
[9]LoRusso PM. Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment[J]. Oncology,2013, 84(1):43-56.
[10]冯萍,陈斌,王亚兵. mTOR信号通路途径与乳腺癌[J].黑龙江医药, 2012, 25(6):842-844.
[11] Gombos A, Barthlmy P, Awada A. Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer[J]. Expert Opin Drug Metab Toxicol, 2015,11(5):823-834.
[12]汤琦,陈德滇,蔡尚立,等.乳腺癌内分泌治疗耐药分子机制的研究进展[J].中华乳腺病杂志:电子版, 2018, 12(5):306-311.
[13] Farzaneh S, Zarghi A. Estrogen receptor ligands:a review(2013-2015)[J].Sci Pharm, 2016, 84(3):409-427.
[14] Pejerrey SM, Dustin D, Kim JA, et al. The impact of ESR1mutations on the treatment of metastatic breast cancer[J].Horm Cancer, 2018, 9(4):215-228.
[15] Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer[J]. Nat Genetm,2013, 45(12):1439-1445.
[16]邓颖斐,薛聪,安欣,等.依维莫司和氟维司群在内分泌耐药晚期乳腺癌中的疗效对比[J].实用医学杂志,2018, 34(10):1581-1584.
[17] Yamnik RL, Holz MK. mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation[J]. Febs Letters, 2010, 584(1):124-128.
[18] Bostner J, Karlsson E, Pandiyan MJ, et al. Activation of Akt,mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit[J]. Breast Cancer Res Treat, 2013, 137(2):397-406.
[19] Simoncini T, Hafezi-Moghadam A, Brazil DP, et al.Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase[J]. Nature, 2000, 407(6803):538-541.
[20] Santen RJ, Fan P, Zhang Z, et al. Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and-resistant breast cancer cells[J].Steroids, 2009, 74(7):586-594.
[21] Yamnik RL, Digilova A, Davis DC, et al. S6 kinase 1 regulates estrogen receptorαin control of breast cancer cell proliferation[J]. J Biol Chem, 2009, 284(10):6361-6369.
[22]李惠平.依维莫司在激素受体阳性晚期乳腺癌治疗中的应用[J].中国新药杂志, 2013, 22(17):2043-2045, 2052.
[23] Zhao M, Ramaswamy B. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer[J]. World J Clin Oncol, 2014, 5(3):248-262.
[24] Hortobagyi GN. Everolimus plus exemestane for the treatment of advanced breast cancer:a review of subanalyses from BOLERO-2[J]. Neoplasia, 2015, 17(3):279-288.
[25] Pritchard KI, Burris HA,Ito Y, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2[J]. Clin Breast Cancer, 2013,13(6):421-432.
[26] Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR(+)breast cancer:BOLERO-2 final progressionfree survival analysis[J]. Adv Ther, 2013, 30(10):870-884.
[27] Porta C, Osanto S, Ravaud A, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma[J]. Eur J Cancer, 2011, 47(9):1287-1298.
[28] Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma:review of adverse event management strategies[J]. J Natl Cancer Inst, 2012, 104(2):93-113.
[29] Jerusalem G, Mariani G, Ciruelos EM, et al. Safety of everolimus plus exemestane in patients with hormonereceptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors:primary results of a phaseⅢb, openlabel, single-arm, expanded-access multicenter trial(BALLET)[J]. Ann Oncol, 2016, 27(9):1719-1725.
[30] Bachelot T, Bourgier C, Cropet C, et al. Randomized phaseⅡtrial of everolimus in combination with tamoxifen in patients with hormone receptorpositive, human epidermal growth factor receptor 2-negativemetastatic breastcancer with prior exposure to aromatase inhibitors:a GINECO study[J].J Clin Oncol, 2012, 30(22):2718-2724.
[31] Royce M, Bachelot T, Villanueva C, et al. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer:A clinical trial[J]. JAMA Oncol, 2018, 4(7):977-984.